184 related articles for article (PubMed ID: 34762523)
1. Liver abscess after drug-eluting bead chemoembolization in patients with metastatic hepatic tumors.
Ye T; Zhu P; Liu Z; Ren Q; Zheng C; Xia X
Br J Radiol; 2022 Jan; 95(1129):20211056. PubMed ID: 34762523
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of liver abscess and biloma formation after drug-eluting bead transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma.
Bian L; Yang J; Song Z
Arab J Gastroenterol; 2024 May; 25(2):176-181. PubMed ID: 38388217
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of combination treatment of drug-eluting bead transarterial chemoembolization and immune checkpoint inhibitors for hepatocellular carcinoma: An increased risk of liver abscess with treatment interval less than one month.
Chiu SH; Lin HH; Feng AC; Lo CH; Hsieh CB; Chen PK; Chang WC
Eur J Radiol; 2024 Jan; 170():111266. PubMed ID: 38185027
[TBL] [Abstract][Full Text] [Related]
5. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
6. Liver abscess after drug-eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management.
Wang LJ; Yin L; Liu KC; Lv WF; Lu D
Hepatol Res; 2024 Apr; 54(4):358-367. PubMed ID: 37924506
[TBL] [Abstract][Full Text] [Related]
7. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
8. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE).
Nakano MM; Yamamoto A; Nishida N; Hamuro M; Hamamoto S; Jogo A; Sohgawa E; Kageyama K; Minami T; Miki Y
Jpn J Radiol; 2019 Jul; 37(7):543-548. PubMed ID: 31055710
[TBL] [Abstract][Full Text] [Related]
10. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG
Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
[TBL] [Abstract][Full Text] [Related]
11. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
[TBL] [Abstract][Full Text] [Related]
13. Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma.
Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Nakano M; Okamura S; Noda Y; Kamachi N; Sakai M; Suzuki H; Nomiyama M; Kuromatsu R; Koga H; Torimura T
Oncology; 2020; 98(8):558-565. PubMed ID: 32422633
[TBL] [Abstract][Full Text] [Related]
14. Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors.
Woo S; Chung JW; Hur S; Joo SM; Kim HC; Jae HJ; Park JH
AJR Am J Roentgenol; 2013 Jun; 200(6):1370-7. PubMed ID: 23701078
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
[TBL] [Abstract][Full Text] [Related]
16. Diffuse biliary peritonitis secondary to rupture of metastatic liver adenocarcinomas after drug-eluting bead transcatheter arterial chemoembolization: a case report.
Zhu LB; Li TF; Li JQ; Li PF; Zhang PB; Wu HB; Xv R
J Int Med Res; 2019 Jun; 47(6):2679-2686. PubMed ID: 30971156
[TBL] [Abstract][Full Text] [Related]
17. Comparative Study of the Short-Term Efficacy and Safety between DEB-TACE and C-TACE in the Treatment of Unresectable Hepatocellular Carcinoma, a Retrospective Study.
Hai L; Liu S; Ma L; Ding X; Bai X; Luo X
Technol Cancer Res Treat; 2024; 23():15330338241250315. PubMed ID: 38773767
[No Abstract] [Full Text] [Related]
18. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.
Monier A; Guiu B; Duran R; Aho S; Bize P; Deltenre P; Dunet V; Denys A
Eur Radiol; 2017 Apr; 27(4):1431-1439. PubMed ID: 27436016
[TBL] [Abstract][Full Text] [Related]
19. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
Li J; Shi C; Shi J; Song J; Wang N
Medicine (Baltimore); 2021 Nov; 100(44):e27636. PubMed ID: 34871232
[TBL] [Abstract][Full Text] [Related]
20. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.
Pipa-Muñiz M; Castells L; Pascual S; Fernández-Castroagudín J; Díez-Miranda I; Irurzun J; Díaz-Beveridge R; Senosiaín M; Arenas J; de la Mata M; Turnes J; Monge-Romero MI; Pérez-Enguix D; Bustamante-Schneider J; Otegui N; Molina-Pérez E; Rodríguez-Menéndez JE; Varela M
Gastroenterol Hepatol; 2017 Oct; 40(8):515-524. PubMed ID: 28676199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
